One year in review
One year in review 2016: Sjögren’s syndrome
F. Ferro1, R. Vagelli2, C. Bruni3, G. Cafaro4, E. Marcucci5, E. Bartoloni6, C. Baldini7
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Florence, Italy.
- Rheumatology Unit, University of Perugia, Italy.
- Rheumatology Unit, University of Perugia, Italy.
- Rheumatology Unit, University of Perugia, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. chiara.baldini74@gmail.com
CER9361
2016 Vol.34, N°2
PI 0161, PF 0171
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 27095672 [PubMed]
Received: 21/02/2016
Accepted : 22/02/2016
In Press: 13/04/2016
Published: 13/04/2016
Abstract
Sjögren’s syndrome (SS) is a complex heterogeneous disease charactered by a broad spectrum of clinical and serological manifestations, including non-Hodgkin’s lymphoma (NHL). Last year, 2015, was an exciting year for research into SS with novel insights into disease pathogenesis, clinical aspects and long-term outcomes. In addition, the use of biologic therapy in SS is rapidly expanding, with new evidence emerging regarding potential therapeutic targets. In this article, we will provide an overview of the recent literature on the pathogenesis, clinical features and novel treatments of SS.
